Re-appointment of Cost Auditors for the FY 2026-27
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Akums Drugs and Pharmaceuticals reported audited standalone FY2026 results with profit after tax of Rs 1,116.40 million, down 31% from Rs 1,609.98 million in FY2025. Revenue from operations was Rs 13,487.36 million for the year. The Board recommended a final dividend of Rs 1 per share plus a special dividend of Rs 2 per share (total Rs 3 per share), with record date July 3, 2026, subject to shareholder approval at the 22nd AGM on July 10, 2026. The company reappointed M/s Balwinder & Associates as Cost Auditors (Rs 3 lakh remuneration) and appointed Mahajan & Aibara LLP as Internal Auditors for FY 2026-27. Mr. V Jagannathan was appointed President-HR, succeeding Mr. Arvind Srivastava. The auditors issued an unmodified report but drew attention to an ongoing Income Tax search and seizure operation from January 2025 and subsequent show cause notices, with impact not yet ascertainable. Exceptional items of Rs 65.19 million were recorded for new labour code impact and VDA arrears.
Profit decline of 31% year-over-year may concern investors, though the special dividend provides shareholder reward. Ongoing IT tax proceedings remain a watch item for investors. The management transition in HR and auditor appointments are routine governance matters with limited stock impact.